Noema Pharma AG closes Series B financing
Noema Pharma AG receives €104m in oversubscribed Series B financing round to advance its central nervous system pipeline.
CNS specialist Noema Pharma has cashed in €104m in an oversubscribed Series B fianancing co-led by Jeito Capital and Forbion. New investors such as the UPMC Enterprises joined by existing investors Sofinnova Partners, Polaris Partners, Gilde Healthcare and Invus.
The raised assets will be used to progress the companys clinical-stage candidates, including its lead compound basimglurant (NOE-101), a mGluR5 inhibitor currently being tested in Phase IIb clinical studies for extreme pain in Trigeminal Neuralgia and seizures in Tuberous Sclerosis Complex. Another candidate is gemlapodect (NOE-105), a PDE10a inhibitor that is being tested in Phase IIb clinical trials for Tourette Syndrome and Childhood Onset Fluency Disorder or Stuttering, a third asset is NOE-115, a triple reuptake inhibitor that is ready for Phase II trials for Atypical Depression and Binge Eating Disorder.
The investors displayed their trust in the company and their commitment to fostering the emergence of global biopharma businesses.
